Table 2 Clinical outcomes based on C. difficile assay result among patients with inflammatory bowel disease
Outcomes | Screen positive/toxin positive, n = 25 | Screen positive/toxin negative, n = 136 | Negative screen, n = 139 | P-value |
|---|---|---|---|---|
CDI Therapy | ||||
No treatment, n (%) | 1 (4) | 22 (16.8) | - | 0.128 |
Metronidazole, n (%) | 2 (8) | 7 (5.1) | - | 0.665 |
Vancomycin, n (%) | 20 (80) | 87 (64) | - | 1 |
Metronidazole and vancomycin, n (%) | 1 (4) | 10 (7.4) | - | 0.688 |
Fidaxomicin, n (%) | 1 (4) | 2 (1.5) | - | 0.41 |
Fecal microbiota transplant, n (%) | 0 (0) | 3 (2.2) | - | 1 |
Primary and secondary outcomes | ||||
Death within 30 days, n (%) | 0 (0) | 2 (2.8) | 2 (1.4) | 0.715 |
Total colectomy or diverting ostomy, n (%) | 0 (0) | 3 (2.2) | 8 (5.8) | 0.175 |
ICU admission, n (%) | 1 (4) | 2 (1.5) | 1 (0.7) | 0.413 |
Primary combined outcome, n (%) | 1 (4) | 6 (4.4) | 10 (7.2) | 0.566 |
Escalation in IBD therapy, n (%) | 7 (28) | 29 (21.3) | 39 (28.1) | 0.408 |
Inpatient setting, n (%) | 12 (48) | 62 (45.9) | 103 (74.1) | < 0.0001 |
Inpatient LOS, d, mean (SD) | 11.6 (22.2) | 8 (9) | 11.8 (14.1) | 0.395 |
Admission to the hospital among outpatients, n (%) | 1 (8.3) | 7 (10.1) | 3 (8.3) | 0.947 |
Readmission to the hospital among inpatients, n (%) | 2 (16.7) | 13 (19.4) | 15 (14.7) | 0.724 |
Laboratory values | ||||
WBC, 103/µL, mean (SD) | 13.2 (10.7) | 11 (5.8) | 11.9 (6.2) | 0.613 |
Hgb, g/dL, mean (SD) | 11.6 (2.7) | 11.4 (2.6) | 10.2 (2) | 0.001 |
Albumin, g/dL, mean (SD) | 3.5 (0.9) | 3.6 (0.8) | 3.2 (0.9) | < 0.001 |
C-reactive protein, mg/L, mean (SD) | 82.5 (113.8) | 30.3 (53.3) | 35.1 (55.5) | 0.593 |